Friday 6-6-2014 Prana Biotechnology Ltd (PRAN) $PRAN opened at 1.75 hitting the high price of 1.80 and a day low of 1.74 with a total volume of 215,300. PRAN had a previous close of 1.77 and has been seeing an average volume of 1,338,485.
Overall Average: 64% Sell
Recent stock forum discussions about PRAN http://investorshangout.com/search?q=PRAN&...mp;yt0=Go!
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer (full story)
Here's the Next Small-Cap Stock the Spec Money Will Chase
at The Street - Wed May 28, 10:33AM CDT
Speculative money has returned to the markets with a vengeance in the small-cap arena. (full story)
Prana Biotechnology (PRAN) Stock Suddenly Surges
at The Street - Tue May 27, 2:28PM CDT
Prana Biotechnology (PRAN) is surging today despite a lack of any significant news regarding the company, which develops drugs to treat neurodegenerative diseases. (full story)
Hot Stock: Prana Biotechnology, Shares Gain 6.4% (PRAN)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 6.4% to $1.67 on 1.0x average daily volume. Prana Biotechnology has traded 1.1 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.4%) during today's trading. (full story)
Biotech Equities Coverage -- Research on Isis Pharma, Pharmacyclics, Prana Biotech, and United Therapeutics
PR Newswire - Mon May 19, 10:29AM CDT
On Friday, May 16, 2014, the NASDAQ Composite ended at 4,090.59, up 0.52%, the Dow Jones Industrial Average finished the day 0.27% higher at 16,491.31, and the S&P 500 closed at 1,877.86, up 0.37%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.93, up 0.35%, and the index has advanced 2.03% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Prana Biotechnology Ltd (NASDAQ: PRAN) and United Therapeutics Corporation (NASDAQ: UTHR). Free technical research on ISIS, PCYC, PRAN and UTHR can be downloaded upon signing up at: (full story)
World leader in movement disorders Professor Ira Shoulson joins Prana Board
PR Newswire - Wed May 14, 6:30AM CDT
Prana Biotechnology (ASX BT, NASDAQ: PRAN) is pleased to announce Professor Ira Shoulson will join the Company's Board of Directors as a Non-Executive Director. (full story)
Biotech and the Fallacy of Analyst Ratings
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 11:05AM CDT
The health-care sector can be volatile, and it's oftentimes not for the faint of heart. While there are tried-and-true conglomerates such as Johnson & Johnson , and big pharmaceutical companies like Pfizer can deliver somewhat predictable... (full story)
Technical Report on Top Gainers -- Research on Centene, Prana Biotechnology, Horizon Pharma, and Scientific Games
PR Newswire - Wed Apr 23, 10:34AM CDT
On Tuesday, April 22, 2014, the NASDAQ Composite ended at 4,161.46, up 0.97%, the Dow Jones Industrial Average finished the session 0.40% higher at 16,514.37, and the S&P 500 closed at 1,879.55, up 0.41%. The gains were broad based as eight out of ten sectors finished on a higher note. A number of stocks saw large movements, including Centene Corp. (NYSE: CNC), Prana Biotechnology Ltd (NASDAQ: PRAN), Horizon Pharma Inc. (NASDAQ: HZNP) and Scientific Games Corp. (NASDAQ: SGMS). Free technical research on CNC, PRAN, HZNP and SGMS can be downloaded upon signing up at: (full story)
Zeldes Haeggquist & Eck LLP Announces Investigation of Prana Biotechnology Limited
Business Wire - Wed Apr 23, 8:02AM CDT
Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into Prana Biotechnology Limited ("Prana Biotechnology" or the "Company"
(NASDAQ: PRAN). The investigation is related to potential violations of federal securities laws and other violations. (full story)
A Beaten-Down Biotech Stock Poised to Perk Up
at The Street - Tue Apr 22, 1:05PM CDT
The biotech sector is back in vogue today. Keep this beaten-down biotech stock on your radar. (full story)
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. (full story)
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ... (full story)
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes. (full story)
Why Prana Biotechnology (PRAN) Stock Is Down Today
at The Street - Tue Apr 01, 9:13AM CDT
Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant... (full story)
Downgrade Alert for Prana Biotechnology (PRAN)
Comtex SmarTrend(R) - Tue Apr 01, 7:03AM CDT
Prana Biotechnology (NASDAQ RAN) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $2.80 on volume of 23.6 million shares, above average daily volume of 2.9 million. In the past 52 weeks, shares of Prana Biotechnology have traded between a low of $2.12 and a high of $13.29 and closed yesterday at $2.80, which is 32% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.3% while the 50-day MA has advanced 0.6%. (full story)
Coca-Cola Falls as Soda Sales Drop for 9th Straight Year
ACCESSWIRE - Tue Apr 01, 12:59AM CDT
Bank of America Corporation (NYSE: BAC) - For an in-depth report on Bank of America Corporation follow: www.BullTrends.com/stockquote/BAC (full story)
Investor Beat: The End of the First Quarter -- How Did We Do?
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:50PM CDT
The first quarter of 2014 officially wrapped up today, and though the Dow, Nasdaq and S&P were all up today, the quarter itself was the worst since the end of 2012. Are stocks finally pulling back enough for investors to find value on the market... (full story)
Overall Average: 64% Sell
Recent stock forum discussions about PRAN http://investorshangout.com/search?q=PRAN&...mp;yt0=Go!
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer (full story)
Here's the Next Small-Cap Stock the Spec Money Will Chase
at The Street - Wed May 28, 10:33AM CDT
Speculative money has returned to the markets with a vengeance in the small-cap arena. (full story)
Prana Biotechnology (PRAN) Stock Suddenly Surges
at The Street - Tue May 27, 2:28PM CDT
Prana Biotechnology (PRAN) is surging today despite a lack of any significant news regarding the company, which develops drugs to treat neurodegenerative diseases. (full story)
Hot Stock: Prana Biotechnology, Shares Gain 6.4% (PRAN)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's best performing low-priced stocks, up 6.4% to $1.67 on 1.0x average daily volume. Prana Biotechnology has traded 1.1 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.4%) during today's trading. (full story) Biotech Equities Coverage -- Research on Isis Pharma, Pharmacyclics, Prana Biotech, and United Therapeutics
PR Newswire - Mon May 19, 10:29AM CDT
On Friday, May 16, 2014, the NASDAQ Composite ended at 4,090.59, up 0.52%, the Dow Jones Industrial Average finished the day 0.27% higher at 16,491.31, and the S&P 500 closed at 1,877.86, up 0.37%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.93, up 0.35%, and the index has advanced 2.03% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Prana Biotechnology Ltd (NASDAQ: PRAN) and United Therapeutics Corporation (NASDAQ: UTHR). Free technical research on ISIS, PCYC, PRAN and UTHR can be downloaded upon signing up at: (full story)
World leader in movement disorders Professor Ira Shoulson joins Prana Board
PR Newswire - Wed May 14, 6:30AM CDT
Prana Biotechnology (ASX
BT, NASDAQ: PRAN) is pleased to announce Professor Ira Shoulson will join the Company's Board of Directors as a Non-Executive Director. (full story) Biotech and the Fallacy of Analyst Ratings
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 11:05AM CDT
The health-care sector can be volatile, and it's oftentimes not for the faint of heart. While there are tried-and-true conglomerates such as Johnson & Johnson , and big pharmaceutical companies like Pfizer can deliver somewhat predictable... (full story)
Technical Report on Top Gainers -- Research on Centene, Prana Biotechnology, Horizon Pharma, and Scientific Games
PR Newswire - Wed Apr 23, 10:34AM CDT
On Tuesday, April 22, 2014, the NASDAQ Composite ended at 4,161.46, up 0.97%, the Dow Jones Industrial Average finished the session 0.40% higher at 16,514.37, and the S&P 500 closed at 1,879.55, up 0.41%. The gains were broad based as eight out of ten sectors finished on a higher note. A number of stocks saw large movements, including Centene Corp. (NYSE: CNC), Prana Biotechnology Ltd (NASDAQ: PRAN), Horizon Pharma Inc. (NASDAQ: HZNP) and Scientific Games Corp. (NASDAQ: SGMS). Free technical research on CNC, PRAN, HZNP and SGMS can be downloaded upon signing up at: (full story)
Zeldes Haeggquist & Eck LLP Announces Investigation of Prana Biotechnology Limited
Business Wire - Wed Apr 23, 8:02AM CDT
Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into Prana Biotechnology Limited ("Prana Biotechnology" or the "Company"
(NASDAQ: PRAN). The investigation is related to potential violations of federal securities laws and other violations. (full story) A Beaten-Down Biotech Stock Poised to Perk Up
at The Street - Tue Apr 22, 1:05PM CDT
The biotech sector is back in vogue today. Keep this beaten-down biotech stock on your radar. (full story)
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. (full story) The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ... (full story)
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes. (full story)
Why Prana Biotechnology (PRAN) Stock Is Down Today
at The Street - Tue Apr 01, 9:13AM CDT
Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant... (full story)
Downgrade Alert for Prana Biotechnology (PRAN)
Comtex SmarTrend(R) - Tue Apr 01, 7:03AM CDT
Prana Biotechnology (NASDAQ
RAN) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $2.80 on volume of 23.6 million shares, above average daily volume of 2.9 million. In the past 52 weeks, shares of Prana Biotechnology have traded between a low of $2.12 and a high of $13.29 and closed yesterday at $2.80, which is 32% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.3% while the 50-day MA has advanced 0.6%. (full story) Coca-Cola Falls as Soda Sales Drop for 9th Straight Year
ACCESSWIRE - Tue Apr 01, 12:59AM CDT
Bank of America Corporation (NYSE: BAC) - For an in-depth report on Bank of America Corporation follow: www.BullTrends.com/stockquote/BAC (full story)
Investor Beat: The End of the First Quarter -- How Did We Do?
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:50PM CDT
The first quarter of 2014 officially wrapped up today, and though the Dow, Nasdaq and S&P were all up today, the quarter itself was the worst since the end of 2012. Are stocks finally pulling back enough for investors to find value on the market... (full story)
